FDA advisory panelist outlines issues with aducanumab's approval for Alzheimer's disease
Below please find a summary for a new article that will be published today in Annals of Internal Medicine. The summary is not intended to substitute for the full article as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf of the organization they represent.
FDA advisory panelist outlines numerous issues with aducanumab's accelerated approval for Alzheimer's disease
Abstract: https://www.acpjournals.org/doi/10.7326/M21-2603
URL ...










